Pancreatic Cancer Trial, Recruiting NCT07273409 Sponsor: Uppsala University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT07273409
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with stage 4 pancreatic neuroendocrine tumour (a specific type of tumour in the pancreas), confirmed by a CT scan or PET/CT scan
  • People whose tumour has been confirmed as a low-to-intermediate grade pancreatic neuroendocrine tumour (Grade 1 or 2) through a tissue or cell sample test
  • People aged 18 years or older
  • People who have given written agreement to take part in the trial

Who may not be able to join:

  • People whose general health or age makes them unsuitable for surgery, as assessed by the medical team
  • People whose surgery has been judged too risky by the surgical team or specialist panel
  • People who have previously had surgery for a pancreatic neuroendocrine tumour
  • People experiencing hormone-related symptoms from their tumour that cannot be controlled with medication and that would require surgery to reduce tumour size
  • People who have previously taken part in this same trial
  • People who are pregnant
  • People whose tumour does not fit into either of the trial's two specific treatment groupings — one group requires that at least 70% of the total tumour can be surgically removed, and the other requires that certain scan findings meet specific criteria (confirm with trial site)
  • People excluded for other reasons judged by the lead researcher to make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Olov Norlén, MD, PhD, Uppsala University Hospital

Phone: +46 18 611 00 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Uppsala University
Registry
ClinicalTrials.gov
Start date
9 January 2026
Est. completion
31 May 2033

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov